Pages that link to "Q46472074"

The following pages link to Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer (Q46472074):

Displaying 48 items.

• Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis (Q26866144) (← links)
• Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN (Q27335766) (← links)
• Breast cancer chemoprevention: old and new approaches (Q27693259) (← links)
• Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance (Q28237217) (← links)
• Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer (Q28483867) (← links)
• Spheroid-based drug screen: considerations and practical approach (Q30052394) (← links)
• Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity (Q33345588) (← links)
• A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis (Q33423855) (← links)
• Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (Q33705425) (← links)
• Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1. (Q33799125) (← links)
• Rapamycin extends maximal lifespan in cancer-prone mice (Q33816255) (← links)
• Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes (Q33849666) (← links)
• A phase I study of sirolimus and bevacizumab in patients with advanced malignancies (Q33977969) (← links)
• Control of mammary tumor differentiation by SKI-606 (bosutinib) (Q34398204) (← links)
• Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies (Q34795914) (← links)
• The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo (Q34805346) (← links)
• Prediction of individual response to anticancer therapy: historical and future perspectives (Q35024682) (← links)
• Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention (Q35106935) (← links)
• Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage (Q35563024) (← links)
• NCI's provocative questions on cancer: some answers to ignite discussion (Q35764401) (← links)
• Autophagy regulates Wolbachia populations across diverse symbiotic associations (Q36056638) (← links)
• Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan (Q36245636) (← links)
• Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin. (Q36569202) (← links)
• The ErbB2 signaling network as a target for breast cancer therapy (Q36583512) (← links)
• Investigating mammalian target of rapamycin inhibitors for their anticancer properties (Q36600294) (← links)
• VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer (Q36656352) (← links)
• Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids (Q36741548) (← links)
• Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations (Q36742629) (← links)
• Obesity, energy balance, and cancer: new opportunities for prevention (Q36810924) (← links)
• Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer (Q36926010) (← links)
• Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions (Q36926148) (← links)
• Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer (Q37335142) (← links)
• Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer (Q37705646) (← links)
• Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents (Q37714306) (← links)
• Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients? (Q38328785) (← links)
• Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression (Q38830963) (← links)
• Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1-Bad-Bak pathway in peritoneal carcinomatosis (Q38988038) (← links)
• mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids (Q39977210) (← links)
• Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model (Q40182123) (← links)
• Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer (Q41970207) (← links)
• Immunosuppressants in cancer prevention and therapy (Q42505783) (← links)
• Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer (Q42561379) (← links)
• Precancer in mice: animal models used to understand, prevent, and treat human precancers (Q44849422) (← links)
• Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin. (Q47217432) (← links)
• Site-specific bioalkylation of rapamycin by the RapM 16-O-methyltransferase. (Q49272873) (← links)
• Dietary energy balance modulation of epithelial carcinogenesis: a role for IGF-1 receptor signaling and crosstalk. (Q54571481) (← links)
• Insights from transgenic mouse models of ERBB2-induced breast cancer (Q80188238) (← links)
• Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023) (Q89848579) (← links)